Does repigmentation mean my vitiligo is cured?
Short answerNo. Repigmentation describes color returning in an area; it does not prove that vitiligo cannot become active again or appear elsewhere. Vitiligo has treatment options, but there is no guaranteed permanent cure. Evidence Evidence
More detail
Guidelines distinguish treatment response from long-term disease course. The biological and visible course varies, and a clinician may assess activity separately from the amount of color present.
What depends on your situation
No snapshot can predict durability. The meaning of a visible change also depends on body site, treatment, time, and how the change was assessed.
Questions for the next review
- How are you distinguishing repigmentation from current disease activity?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Can pigment be lost again?
Short answerYes, relapse can occur, but the chance and timing are not identical for every person, body site, or treatment. A return of lighter skin deserves documentation and clinical review rather than an assumption that you caused it. Evidence Evidence
More detail
Clinical guidance recognizes relapse and the need to discuss durability. Some studies follow outcomes after treatment ends, but group follow-up cannot forecast one person’s skin.
What depends on your situation
Evidence is incomplete across treatments and long-term populations. Lighting and camera differences can also imitate change in personal photographs.
Questions for the next review
- What change should bring me back for review?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Should I continue something as maintenance?
Short answerThat is an exact-treatment decision, not a universal rule. A maintenance discussion should name the goal, treatment, evidence, risks, effort, and review point. It should also state what would lead to a change or stop. Evidence Evidence
More detail
Consensus guidance discusses maintenance in selected contexts, while labels and safety requirements remain product-specific. Continuing treatment indefinitely should not be assumed from the word “maintenance.”
What depends on your situation
If maintenance is considered, your clinician must define its goal, evidence, risks, burden, and plan.
Questions for the next review
- What evidence supports maintenance with this exact treatment?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What will we review, and what would make us stop?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if my definition of success has changed?
Short answerYou can revisit the goal. Success may mean color returning, fewer new changes, or a routine you can sustain. It may also mean feeling more in control, choosing camouflage, or deciding active treatment is not worth the burden. Evidence Evidence
More detail
Shared decisions include the effect of vitiligo and treatment on daily life, not only a clinical score. Acceptance and treatment can coexist; neither is morally superior.
What depends on your situation
You decide which priorities matter most. Changing a treatment plan does not guarantee an improvement in mood or skin.
Questions for the next review
- Can we restate the goal in terms that matter to me now?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
One evidence record, 2 statements
No. Repigmentation describes color returning in an area; it does not prove that vitiligo cannot become active again or appear elsewhere. Vitiligo has treatment options, but there is no guaranteed permanent cure.
Yes, relapse can occur, but the chance and timing are not identical for every person, body site, or treatment. A return of lighter skin deserves documentation and clinical review rather than an assumption that you caused it.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Thomas KS, et al.)Randomized trial · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.